886762-75-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-3-fluoro-2-nitroaniline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drug molecules with specific therapeutic properties. Its unique structural features allow for the creation of compounds with targeted biological activities, making it valuable in the design of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Bromo-3-fluoro-2-nitroaniline is employed as a building block in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, thereby contributing to improved crop protection and yield.
Used in Dye Industry:
4-Bromo-3-fluoro-2-nitroaniline is utilized as a starting material in the synthesis of dyes, particularly those with specific color properties and stability. Its presence in the dye molecules can impart unique characteristics, such as resistance to fading and improved solubility, making it an essential component in the formulation of various dye products.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 4-Bromo-3-fluoro-2-nitroaniline plays a crucial role in the preparation of a wide range of organic compounds. Its reactivity and functional groups make it a versatile building block for the synthesis of various chemical entities, including complex organic molecules and specialty chemicals.
Used in Chemical Production:
4-Bromo-3-fluoro-2-nitroaniline serves as an essential intermediate in the production of other chemicals, where its unique structural features are exploited to generate a diverse array of chemical products. Its role in this process highlights its importance in the broader chemical industry and the synthesis of various compounds with specific applications.

Upstream product

• 19064-24-5 2,6-difluoro-1-nitrobenzene 

Relevant academic research and scientific papers

LIPOXYGENASE INHIBITORS

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.